|
KMID : 1102220230430010039
|
|
Kidney Research and Clinical Practice
2023 Volume.43 No. 1 p.39 ~ p.52
|
|
|
Uremic pruritus: pathophysiology, clinical presentation, and treatments
|
|
Mei-Ju Ko
Yu-Sen Peng
Hon-Yen Wu
|
|
|
Abstract
|
|
|
|
Uremic pruritus is one of the most common and bothersome symptoms in patients with end-stage renal disease. Most patients withuremic pruritus experience a prolonged and relapsing course and significant impairments of quality of life. The pathophysiology of uremicpruritus is not completely understood. A complex interplay among cutaneous biology and the nervous and immune systems hasbeen implicated, with the involvement of various inflammatory mediators, neurotransmitters, and opioids. Uremic pruritus treatmentoutcomes are often unsatisfactory. Clinical trials have mostly been small in scale and have reported inconsistent results. Recent evidenceshows that gabapentinoids, nalfurafine, and difelikefalin are effective for relieving uremic pruritus in hemodialysis patients.This review provides an overview of the epidemiology and proposed mechanisms of uremic pruritus, then highlights the manifestationsof and clinical approach to uremic pruritus. Current evidence regarding treatment options, including topical treatments, treatmentof underlying disease, phototherapy, and systemic treatments, is also outlined. With a better understanding of uremic pruritus,more therapeutic options can be expected in the near future.
|
|
|
KEYWORD
|
|
|
Gabapentin, Chronic kidney failure, Pregabalin, Pruritus, Chronic renal insufficiency
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|
|